Quantcast
Last updated on April 16, 2014 at 17:27 EDT

Latest Virosome Stories

2014-01-06 04:21:45

In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics TOKYO, ROCKVILLE, Md. and EPALINGES, Switzerland, Jan. 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched...

2012-11-08 08:33:41

ITTIGEN, Switzerland, November 8, 2012 /PRNewswire/ -- - Patent already granted in Europe - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of...

2012-03-08 06:02:00

BERN, Switzerland, March 8, 2012 /PRNewswire/ -- - Quality of Life (QoL) is strongly diminished in RVVC patients - Current available treatment fails in two thirds of patients - High medical need demands novel effective treatment options Pevion Biotech AG today announced results from a large, international survey on the Quality of Life (QoL) of recurrent vulvovaginal candidiasis (RVVC) patients. It is the first time that the overall disease...

2012-01-17 04:45:00

BERN, Switzerland, January 17, 2012 /PRNewswire/ -- Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens. Following the...

2011-10-11 05:36:00

BERN, Switzerland, October 11, 2011 /PRNewswire/ -- Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international representative epidemiological survey to date on recurrent vulvovaginal candidiasis (RVVC), confirming that 7% of adult women suffer from the...

2011-09-01 04:00:00

BERN, Switzerland, September 1, 2011 /PRNewswire/ -- Pevion Biotech AG today announced that the company has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine in Australia and New Zealand. At the same time, both companies signed a long-term supply agreement under which CSL shall supply to Pevion components for its virosomal vaccines. CSL, Australia's leading biopharmaceutical company, obtained a right of first...

2011-04-21 04:56:00

BERNE, Switzerland, April 21, 2011 /PRNewswire/ -- Pevion Biotech AG today announced that Jean-Paul Prieels has joined its Board of Directors. Until January 2011, Dr. Prieels was Senior Vice President Research and Development at GlaxoSmithKline Biologicals. Jean-Paul Prieels joined GlaxoSmithKline Biologicals in 1987 as Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart,...

2011-02-10 05:49:00

ITTIGEN, Switzerland and BERN, Switzerland, February 10, 2011 /PRNewswire/ -- Pevion Biotech Ltd. today announced the appointment of Didier Hoch as Chairman of its Board of Directors. Until recently, Dr Hoch was President of Sanofi-Pasteur MSD, where he played a pivotal role in launching innovative vaccines, such as Gardasil(R), in Europe. Prior to his position as President of Sanofi-Pasteur MSD from 2000 until 2010, Didier Hoch was Vice President Africa & Middle East at Aventis...

2010-11-11 03:52:00

ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and...

2010-09-07 03:59:00

BERNE, Switzerland, September 7, 2010 /PRNewswire/ -- Pevion Biotech AG announced today the appointment of Evert Kueppers as its new Chief Executive Officer, succeeding Thomas Stauffer. "We would like to thank Thomas for his excellent contributions over the years and wish him all the best in his new position," said Klaus Breiner of BB Biotech Ventures and Chairman of the Board of Directors. "We are very pleased that we could attract Evert to become the new CEO of Pevion. With his...